Candidate drugs against SARS-CoV-2 and COVID-19

Vista sencilla de ítem
dc.creatorMcKee, Dwight L.
dc.creatorSternberg, Ariane
dc.creatorStange, Ulrike
dc.creatorLaufer, Stefan
dc.creatorNaujokat, Cord
dc.date.accessioned2020-08-24T22:18:33Z
dc.date.available2020-08-24T22:18:33Z
dc.date.created2020-07
dc.description.abstractenglishOutbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.spa
dc.format.extent9 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.phrs.2020.104859spa
dc.identifier.issn1043-6618spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S1043661820311671?via%3Dihubspa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/12169
dc.language.isoengspa
dc.publisherPharmacological Researchspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.rights.localAcceso restringidospa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subject.keywordDrugsspa
dc.subject.keywordCamostatspa
dc.subject.keywordChloroquinespa
dc.subject.keywordRemdesivirspa
dc.subject.keywordLopinavirspa
dc.subject.keywordRitonavirspa
dc.subject.keywordFavipiravirspa
dc.subject.keywordArbidolspa
dc.subject.keywordPhytochemicalsspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleCandidate drugs against SARS-CoV-2 and COVID-19spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Candidate-drugs-against-SARS-CoV-2-and-COVID-19_2020_Pharmacological-Researc.pdf
Tamaño:
496.76 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS